British Biotech Pharmaceuticals Limited

Pfizer Corporation

John Martin Clements

Mark Whittaker

Michael George Hunter

Zoe Marie Spavold

Raymond Paul Beckett

Lisa Marie Pratt

Steven Launchbury

Stephen John Davies

Paul Raymond Beckett

Richard Mark Edwards

David Graham Brown

Stewart Craig

Anne L Cook

Compounds of formula (I) or a pharmaceutically or veterinarily acceptable salts thereof wherein Rrepresents hydrogen, C-Calkyl or C-Calkyl substituted by one or more halogen atoms; Rrepresents a group R-(ALK)-, and A represents (i) a group of formula (IA): wherein the compounds inhibit the activity of bacterial PDF enzyme.

Antibacterial agents

A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof: 

Hydroxamic acid derivatives as antibacterials

A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof for the inhibition of activity of bacterial PDF enzyme: wherein A represents a group of formula (IA) or (IB) and wherein Ris hydrogen, Ris n-butyl, benzyl or cyclopentylmethyl, Ris hydrogen, Ris tert-butyl, iso-butyl, benzyl or methyl, Ris hydrogen or methyl and Ris methyl.

A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:

Selected compounds of formula (I) are antibacterial agents: formula (I) wherein Rrepresents a substituted or unsubstituted C-Calkyl, cycloalkyl (C-Calkyl)- or aryl (C-Calkyl)-group, and A represents a group of formula (IA), or (IB) wherein Rrepresents the side chain of a natural or non-natural alpha amino acid, and Rand Rare each independently hydrogen or C-Calkyl, heterocyclic or aryl (C-Calkyl)-, Rand Rwhen taken together with the nitrogen atom to which they are attached from an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring

Antibacterial hydroxamic acid derivatives

Compounds of formula (I) are antibacterials wherein: R represents hydrogen, or C -C alkyl or C -C alkyl substituted by one or more halogen atoms; R represents a group R &mdash;(X) &mdash;(ALK) &mdash; wherein R represents hydrogen, or a C -C alkyl, C -C alkenyl, C -C alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C -C )alkyl, (C -C )alkoxy, hydroxy, mercapto, (C -C )alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, &mdash;COOH, &mdash;CONH , &mdash;COOR , &mdash;NHCOR , &mdash;CONHR , &mdash;NHR , &mdash;NR R , or &mdash;CONR R wherein R and R are independently a (C -C )alkyl group, and ALK represents a straight or branched divalent C -C alkylene, C -C alkenylene, or C -C alkynylene radical, and may be interrupted by one or more non-adjacent &mdash;NH&mdash;, &mdash;O&mdash; or &mdash;S&mdash; linkages, X represents &mdash;NH&mdash;, &mdash;O&mdash; or &mdash;S&mdash;, and m and n are independently 0 or 1; and A represents a group as defined in the specification.

Growing community of inventors

Oxford, United Kingdom

John Martin Clements